Paradigm Biocapital Advisors LP Moon Lake Immunotherapeutics Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 878,323 shares of MLTX stock, worth $47.7 Million. This represents 1.94% of its overall portfolio holdings.
Number of Shares
878,323
Previous 627,423
39.99%
Holding current value
$47.7 Million
Previous $24.5 Million
69.12%
% of portfolio
1.94%
Previous 1.26%
Shares
5 transactions
Others Institutions Holding MLTX
# of Institutions
157Shares Held
54.8MCall Options Held
799KPut Options Held
661K-
Bvf Inc San Francisco, CA19.8MShares$1.07 Billion36.63% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$461 Million40.43% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.15MShares$225 Million3.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.61MShares$142 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.67MShares$90.9 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.01B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...